Acadia Pharmaceuticals, Inc. (ACAD) Tops Q3 EPS by 5c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $21.62 +0.09%
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.04), $0.05 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $1.9 million.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Goldman Sachs Starts Infratil New Zealand (IFT:NZ) at Buy
- Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
